BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

PALO ALTO, Calif., June 03, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along...

Related Keywords

Melbourne ,Victoria ,Australia ,Ravi Savarirayan ,Vikram Bali ,Nasdaq ,Linkedin ,Twitter ,Bridgebio Pharma Inc ,Bio Pharma Inc ,Murdoch Children Research Institute ,Bio Pharma ,Murdoch Children ,Research Institute ,Bridgebio Pharma ,Bio Contact ,